

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

BOX 250 ml/LABEL 1000 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Toltracol 50 mg/ml oral suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains: 50 mg of toltrazuril.

3. PACKAGE SIZE

250 ml
1000 ml

4. TARGET SPECIES

Pigs (Piglets 3 - 5 days old).
Cattle (calves on dairy farms).
Sheep (lambs).



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.
The oral suspension must be shaken before use.

7. WITHDRAWAL PERIODS

Withdrawal periods:

	Pigs	Cattle	Sheep
Meat and offal:	77 days	63 days	42 days
Milk:	/	Not authorised for use in animals producing milk for human consumption	

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use within 1 year.
Once opened, use by...

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

LABEL 250 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Tolracol 50 mg/ml oral suspension

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains 50 mg of toltrazuril.

3. TARGET SPECIES

Pigs (Piglets 3 - 5 days old).
Cattle (calves on dairy farms).
Sheep (lambs).



4. ROUTES OF ADMINISTRATION

Read the package leaflet before use.
Oral use.
The oral suspension must be shaken before use.

5. WITHDRAWAL PERIODS

Withdrawal periods:

	Pigs	Cattle	Sheep
Meat and offal:	77 days	63 days	42 days
Milk:	/	Not authorised for use in animals producing milk for human consumption	

6. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use within 1 year.
Once opened, use by...

7. SPECIAL STORAGE PRECAUTIONS

8. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA

9. BATCH NUMBER

Lot {number}

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Toltracol 50 mg/ml oral suspension for pigs, cattle and sheep

2. Composition

Each ml contains:

Active substances:

Toltrazuril 50 mg

Excipients:

Sodium benzoate (E211) 2.1 mg

Sodium propionate (E281) 2.1 mg

Thick white suspension.

3. Target species

Pigs (Piglets 3 - 5 days old).

Cattle (calves on dairy farms).

Sheep (lambs).



4. Indications for use

Pigs:

For the prevention of clinical signs of coccidiosis in neonatal piglets (3 – 5 days) on farms with a confirmed history of coccidiosis caused by *Cystoisospora suis*.

Cattle:

For the prevention of clinical signs of coccidiosis and reduction of oocyst shedding in housed calves replacing cows producing milk for human consumption (dairy cows) on farms with a confirmed history of coccidiosis caused by *Eimeria bovis* or *Eimeria zuernii*.

Sheep:

For the prevention of clinical signs of coccidiosis and reduction of oocyst shedding in lambs on farms with a confirmed history of coccidiosis caused by *Eimeria crandallis* and *Eimeria ovinoidalis*.

5. Contraindications

Do not use cases of hypersensitivity to the active substance or to any of the excipients.
Cattle (for environmental reasons):
Do not use in calves weighing more than 80 kg bodyweight.
Do not use in veal or beef calves.

6. Special warnings

Special precautions for safe use in the target species:

As with any antiparasiticide, frequent and repeated use of antiprotozoals from the same class may lead to the development of resistance.

It is recommended to treat all animals in a pen. Hygienic measures may reduce the risk of coccidiosis. It is therefore, recommended to improve concomitantly the hygienic conditions in the concerned facility, particularly with regard to dryness and cleanliness. To obtain maximum benefit, animals should be treated before the expected onset of clinical signs, i.e. in the prepatent period. Treatment during an outbreak will be of limited value for the individual animal, because of damage to the small intestine having already occurred. To alter the course of an established clinical coccidial infection, in individual animals already showing signs of diarrhoea, additional supportive therapy may be required.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known sensitivity to toltrazuril or any of the excipients should avoid contact with this veterinary medicinal product.

Do not eat, drink or smoke while using the veterinary medicinal product.

Avoid skin and eye contact with the veterinary medicinal product.

Wash any splashes from skin or eyes immediately with water.

Special precautions for the protection of the environment:

The major metabolite of toltrazuril, toltrazuril sulfone (ponazuril), has been shown to be both persistent (half-life > 1 year) and mobile in soil and to be toxic to plants. Given the persistent properties of ponazuril, repeated spreading of manure from treated animals may lead to an accumulation in the soil and consequently a risk to plants. The accumulation of ponazuril in soil together with its mobility also leads to a risk of leaching to groundwater.

In order to prevent any adverse effects on plants and possible contamination of groundwater, manure from treated calves must not be spread onto land without dilution with manure from untreated cattle. Manure from treated calves must be diluted with at least 3 times the weight of manure from untreated cattle before it can be spread onto land.

Lambs kept throughout the whole life span indoors under an intensive rearing system must not be treated beyond the age of 6 weeks or body weight of more than 20 kg at treatment. Manure from treated animals should only be applied to the same piece of land every third year.

Overdose:

No signs of intolerance were reported in healthy piglets and calves after oral administration of threefold overdose. In lambs, no signs of overdose have been observed with threefold overdose at a single treatment and twofold overdose at treatment on two consecutive days.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

Pigs:

Individual animal treatment

Each piglet should be treated on day 3 to 5 of life with a single oral dose of 20 mg toltrazuril per kg body weight corresponding to 0.4 ml oral suspension per kg body weight.

Due to the small volumes required to treat individual piglets, use of dosing equipment with a dose accuracy of 0.1 ml is recommended.

Cattle:

Each animal should be treated with a single oral dose of 15 mg toltrazuril/kg body weight corresponding to 3.0 ml oral suspension per 10 kg body weight.

If animals are to be treated collectively rather than individually, they should be grouped according to their body weight and dosed accordingly, in order to avoid under- or over-dosing.

Sheep:

Each animal should be treated with a single oral dose of 20 mg toltrazuril/kg body weight corresponding to 0.4 ml oral suspension per kg body weight.

If animals are to be treated collectively rather than individually, they should be grouped according to their body weight and dosed accordingly, in order to avoid under- or over-dosing.

9. Advice on correct administration

The oral suspension must be shaken before use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

To obtain maximum benefit, animals should be treated before the expected onset of clinical signs, i.e. in the prepatent period.

10. Withdrawal periods

Pigs:

Meat and offal: 77 days.

Cattle:

Meat and offal: 63 days.

Milk: Not authorised for use in animals producing milk for human consumption.

Sheep:

Meat and offal: 42 days.

Milk: Not authorised for use in animals producing milk for human consumption.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions. Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf-life after first opening the immediate packaging: 1 year.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Tolracol is available in bottles of 250 ml and 1000 ml.

The 250 ml bottle is supplied in a box.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Manufacturer responsible for batch release:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany

Local representatives and contact details to report suspected adverse events:

KRKA UK Ltd

United Kingdom

Tel: 02071 646 156

info.uk@krka.biz

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall
Approved: 08 March 2026